Related Experiment Video
Updated: Oct 1, 2025

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
Multiphysics and multiscale modeling of microthrombosis in COVID-19
He Li1, Yixiang Deng1, Zhen Li2
1School of Engineering, Brown University, Providence, Rhode Island, United States of America.
Insights
Computational modeling reveals key factors in COVID-19 microvascular thrombosis, identifying antithrombin and factor V as critical. White blood cell recruitment exacerbates clot formation, offering new therapeutic targets for Coronavirus disease 2019.
Area of Science:
- Biomedical Engineering
- Computational Biology
- Hematology
Background:
- Microvascular thrombosis is a critical factor in Coronavirus disease 2019 (COVID-19) progression.
- Limited access to patient blood samples hinders in vitro research on SARS-CoV-2 related thrombosis.
- Understanding the mechanisms of COVID-19 associated thrombosis is crucial for developing effective treatments.
Purpose of the Study:
- To develop and utilize a novel computational framework for predictive modeling of pathological thrombus formation in COVID-19 microvasculature.
- To quantify the contributions of various prothrombotic factors implicated in COVID-19.
- To identify potential therapeutic targets for anti-thrombotic treatment in COVID-19 patients.
Main Methods:
- Employed a multiscale and multiphysics computational framework integrating hemodynamics, coagulation factor transport and kinetics, and blood cell mechanics.
- Simulated pathological thrombus formation in microvasculature using data from COVID-19 patients.
- Analyzed the roles of stasis, coagulation factor levels, and inflammatory responses in microthrombus development.
Main Results:
- Antithrombin and factor V were identified as key coagulation factors promoting thrombosis in COVID-19.
- Recruitment of white blood cells (WBCs) to endothelial cells significantly exacerbates thrombogenesis and blood flow blockage.
- Observed flowing blood cell clusters may originate from detached WBCs, potentially forming new clots.
Conclusions:
- The study highlights antithrombin, factor V, and WBC recruitment as critical elements in COVID-19 microvascular thrombosis.
- Findings suggest potential targets for prioritizing anti-thrombotic therapies in COVID-19 management.
- The developed computational framework offers a powerful tool for understanding thrombosis mechanisms and informing therapeutic strategies.
Abstract:
Emerging clinical evidence suggests that thrombosis in the microvasculature of patients with Coronavirus disease 2019 (COVID-19) plays an essential role in dictating the disease progression. Because of the infectious nature of SARS-CoV-2, patients' fresh blood samples are limited to access for in vitro experimental investigations. Herein, we employ a novel multiscale and multiphysics computational framework to perform predictive modeling of the pathological thrombus formation in the microvasculature using data from patients with COVID-19. This framework seamlessly integrates the key components in the process of blood clotting, including hemodynamics, transport of coagulation factors and coagulation kinetics, blood cell mechanics and adhesive dynamics, and thus allows us to quantify the contributions of many prothrombotic factors reported in the literature, such as stasis, the derangement in blood coagulation factor levels and activities, inflammatory responses of endothelial cells and leukocytes to the microthrombus formation in COVID-19. Our simulation results show that among the coagulation factors considered, antithrombin and factor V play more prominent roles in promoting thrombosis. Our simulations also suggest that recruitment of WBCs to the endothelial cells exacerbates thrombogenesis and contributes to the blockage of the blood flow. Additionally, we show that the recent identification of flowing blood cell clusters could be a result of detachment of WBCs from thrombogenic sites, which may serve as a nidus for new clot formation. These findings point to potential targets that should be further evaluated, and prioritized in the anti-thrombotic treatment of patients with COVID-19. Altogether, our computational framework provides a powerful tool for quantitative understanding of the mechanism of pathological thrombus formation and offers insights into new therapeutic approaches for treating COVID-19 associated thrombosis.

